CPMV Mosaic ImmunoEngineering Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 836564 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY0.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,254.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets238,930.6%
Debt / equity—
Current ratio0.00x
Interest coverage-60.40x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-2,078.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $15,608 | $15,880 | $16,133 | $16,039 | $16,006 | $15,803 | $16,250 | $39,599 |
| SG&A expense | $141,113 | $138,922 | $132,000 | $128,319 | $132,848 | $158,971 | $133,907 | $146,831 |
| Operating income | -$156,721 | -$154,802 | -$148,133 | -$144,358 | -$148,854 | -$174,774 | -$150,157 | -$186,430 |
| Interest expense | $2,492 | $2,467 | $2,521 | $2,521 | $2,493 | $2,466 | $3,004 | $2,817 |
| Pretax income | -$177,496 | -$175,351 | -$169,137 | -$165,361 | -$169,628 | -$181,320 | -$150,644 | -$186,730 |
| Income tax | $0 | $0 | $0 | $0 | $2,400 | $0 | $2,400 | $0 |
| Net income | -$177,496 | -$175,351 | -$169,137 | -$165,361 | -$172,028 | -$181,320 | -$153,044 | -$186,730 |
| EPS (basic) | -0.02 | -0.02 | — | -0.02 | -0.02 | -0.03 | — | -0.03 |
| EPS (diluted) | -0.02 | -0.02 | — | -0.02 | -0.02 | -0.03 | — | -0.03 |
| Weighted avg. shares (diluted) | 7.24M | 7.24M | — | 7.24M | 7.24M | 7.24M | — | 7.24M |
| Balance sheet | ||||||||
| Cash & equivalents | $26 | $72 | $3,622 | $31,761 | $53,583 | $85,930 | $115,019 | $5,736 |
| Current assets | $3,278 | $9,828 | $19,882 | $55,298 | $57,699 | $97,784 | $141,611 | $39,950 |
| Total assets | $3,278 | $9,828 | $19,882 | $55,298 | $57,699 | $97,784 | $141,611 | $39,950 |
| Current liabilities | $6.33M | $6.18M | $6.03M | $5.91M | $5.77M | $5.66M | $5.54M | $5.30M |
| Total liabilities | $7.83M | $7.66M | $7.50M | $7.36M | $7.20M | $7.07M | $6.93M | $6.68M |
| Shareholders' equity | -$7.83M | -$7.65M | -$7.48M | -$7.31M | -$7.14M | -$6.97M | -$6.79M | -$6.64M |
| Shares outstanding | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M |
| Cash flow statement | ||||||||
| Operating cash flow | -$46 | -$3,550 | -$28,139 | -$21,822 | -$32,347 | -$29,089 | -$20,717 | -$12,998 |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | — | — | $0 | $0 | — | — | $130,000 | $15,000 |
| Stock-based compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.